Linked-in: design and efficacy of antibody drug conjugates in oncology
about
Antibody-drug conjugates as novel anti-cancer chemotherapeuticsNew antibody approaches to lymphoma therapyNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewMembrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumorsAdo-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell GrowthInotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.Ofatumumab in the treatment of non-Hodgkin's lymphomas.Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.Front-End Electron Transfer Dissociation Coupled to a 21 Tesla FT-ICR Mass Spectrometer for Intact Protein Sequence Analysis.Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.Antibody drug conjugates: lessons from 20 years of clinical experience.Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer.
P2860
Q26800175-A2E349A4-0519-4077-A307-02B94EF3F633Q27022373-E520F78C-9403-4529-B7C3-CA58AD2412F7Q27304386-E909429D-6BE5-4614-94A9-1F44B80AFC71Q30278773-6B54B89F-D0F9-42F7-9D0A-6C42E60BCACEQ33414335-2D224C4A-B2A1-4D11-8116-EF58E9139208Q36316911-4F22BB87-6490-450E-A198-1E79EBE3C420Q38379829-D4F25073-92CA-4274-9EC2-AB2E99A7C226Q38516077-6AFC3ABF-C187-48EA-BA02-A40AD8A4DCE5Q38537257-00A73B38-96E1-493D-9820-B1768D9C2F2AQ38672858-C1261F6B-F184-4019-9318-E22A00C0AA07Q38699173-39C45688-A736-45ED-AC71-6E2F545A9948Q38979084-CAC7707A-EE8D-4756-A05F-F3189066DDAFQ41282870-9B5006A4-851F-4839-B708-3315E2F8DC61Q52672976-20A3F1EB-0B58-4553-87BD-746ABC3F8133
P2860
Linked-in: design and efficacy of antibody drug conjugates in oncology
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Linked-in: design and efficacy of antibody drug conjugates in oncology
@en
Linked-in: design and efficacy of antibody drug conjugates in oncology.
@nl
type
label
Linked-in: design and efficacy of antibody drug conjugates in oncology
@en
Linked-in: design and efficacy of antibody drug conjugates in oncology.
@nl
prefLabel
Linked-in: design and efficacy of antibody drug conjugates in oncology
@en
Linked-in: design and efficacy of antibody drug conjugates in oncology.
@nl
P2093
P2860
P356
P1433
P1476
Linked-in: design and efficacy of antibody drug conjugates in oncology
@en
P2093
Amit K Verma
Carolina Schinke
Ira Braunschweig
Jonathan Feld
Stefan K Barta
P2860
P304
P356
10.18632/ONCOTARGET.924
P407
P577
2013-03-01T00:00:00Z